Portal de Periódicos da CAPES

Comparison of the Effect of Ranibizumab and Verteporfin for Polypoidal Choroidal Vasculopathy: 12-Month LAPTOP Study Results

2013; Elsevier BV; Volume: 156; Issue: 4 Linguagem: Inglês

10.1016/j.ajo.2013.05.024

1879-1891

Akio Oishi, Hiroshi Kojima, Michiko Mandai, Shigeru Honda, Toshiyuki Matsuoka, Hideyasu Oh, Mihori Kita, Tomoko Nagai, Masashi Fujihara, Nobuhiro Bessho, Mamoru Uenishi, Yasuo Kurimoto, Akira Negi,

Retinal and Optic Conditions

Purpose To compare the effect of photodynamic therapy (PDT) and intravitreal ranibizumab in patients with polypoidal choroidal vasculopathy (PCV). Design Randomized clinical trial. Methods setting: Multicenter. study population: Total of 93 patients with treatment-naïve PCV. intervention: Patients were randomized to 2 arms. Patients in the PDT arm underwent a single session of PDT with verteporfin, and patients in the ranibizumab arm received 3 monthly ranibizumab injections at baseline. Additional treatment was performed as needed in each arm. main outcome measures: Primary outcome measurement was the proportion of patients gaining or losing more than 0.2 logarithm of minimal angle of resolution (logMAR) units from baseline. Mean change of logMAR and central retinal thickness (CRT) were also evaluated. Results In the PDT arm (n = 47), 17.0% achieved visual acuity gain, 55.3% had no change, and 27.7% experienced visual acuity loss. The results were 30.4%, 60.9%, and 8.7%, respectively, in the ranibizumab arm (n = 46), significantly better than the PDT arm ( P = .039). In the PDT arm, mean CRT improved (366.8 ± 113.6 μm to 289.1 ± 202.3 μm, P < .001), but logMAR was unchanged (0.57 ± 0.31 to 0.62 ± 0.40). The ranibizumab arm demonstrated improvement in both CRT (418.9 ± 168.6 μm to 311.2 ± 146.9 μm, P < .001) and logMAR (0.48 ± 0.27 to 0.39 ± 0.26, P = .003). Mean change of logMAR was also greater in the ranibizumab arm ( P = .011). Conclusion Intravitreal injection of ranibizumab is more effective than PDT for treatment-naïve PCV.